La cadena de opciones muestra datos clave de las opciones de acciones de Y-mAbs Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Y-mAbs Therapeutics..

Y-mAbs Therapeutics (NASDAQ:YMAB) Bolsa, Cadena de Opciones

Y-mAbs Therapeutics

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.

Y-mAbs Therapeutics Inc

WIIM

ABNB

Airbnb shares are trading lower after the company reported worse-than-expected Q3 financial results and issued Q4 revenue guidance below estimates.

ClearPoint Neuro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLPT#NASDAQ">CLPT</a>) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.17) by 5.88 percent. This is a 10 percent increase over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $8.122 million which beat the analyst consensus estimate of $7.780 million by 4.40 percent. This is a 40.96 percent increase over sales of $5.762 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

CLPT

ClearPoint Neuro Q3 2024 GAAP EPS $(0.18) Misses $(0.17) Estimate, Sales $8.122M Beat $7.780M Estimate

RCM Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCMT#NASDAQ">RCMT</a>) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of $0.38 by 15.79 percent. This is a 12 percent decrease over earnings of $0.50 per share from the same period last year. The company reported quarterly sales of $60.365 million which missed the analyst consensus estimate of $60.445 million by 0.13 percent. This is a 3.99 percent increase over sales of $58.049 million the same period last year.

RCMT

RCM Technologies Q3 2024 Adj. EPS $0.44 Beats $0.38 Estimate, Sales $60.365M Miss $60.445M Estimate

Nephros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEPH#NASDAQ">NEPH</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.02) by 200 percent. The company reported quarterly sales of $3.500 million which beat the analyst consensus estimate of $3.499 million by 0.03 percent. This is a 6.47 percent decrease over sales of $3.742 million the same period last year.

NEPH

Nephros Q3 2024 GAAP EPS $0.02 Beats $(0.02) Estimate, Sales $3.500M Beat $3.499M Estimate

Bitcoin briefly hit a fresh all-time high of $76,872 on Thursday before retreating, with financial markets continuing their rally in the wake of Donald Trump winning a <a href="https://www.benzinga.com/news/large-cap/24/11/41826586/wall-street-closes-at-record-highs-after-reassurance-from-powell-magnificent-7-hit-17-trillion-tre">second term in office</a>.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$75,723.12</td>
<td>-0.3%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$2,879.34&nbsp;</td>
<td>+7%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>&nbsp;$195.34</td>
<td>+3.4%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.1952</td>
<td>-3.1%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00001896</td>
<td>-0.4%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul>
<li>IntoTheBlock data shows large transaction volume increasing by 83% and daily active addresses rising by 17%. </li>
<li>Coinglass data reports 102,336 traders were liquidated in the past 24 hours for $320 million, $200 million of which were liquidated short positions. </li>
</ul>
Notable Developments:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41807557/bitcoin-as-americas-gold-trumps-bitcoin-act-could-reshape-us-reserves-says-coinshares">Bitcoin As America&#8217;s Gold? How Trump&#8217;s Bitcoin Act Could Reshape US Reserves</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41819799/polymarket-ceo-on-election-night-it-looked-like-a-done-deal-on-platform-but-just-watching-">Polymarket CEO On Election Night: &#8216;It Looked Like A Done Deal&#8217; On Platform, But Just Watching TV &#8216;You Would Think It&#8217;s Neck And Neck&#8217;</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41818982/will-microstrategys-42-billion-bitcoin-bet-boost-mstr-stock-further">Will MicroStrategy&#8217;s $42 Billion Bitcoin Bet Boost MSTR Stock Further?</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41814313/dogwifhat-struggles-to-keep-up-with-dogecoin-shiba-inu-what-is-going-on">Dogwifhat Struggles To Keep Up With Dogecoin, Shiba Inu: What Is Going On?</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41823388/the-trump-effect-a-deep-dive-into-how-the-crypto-landscape-will-change-in-2025-and-beyond">The Trump Effect: A Deep Dive Into How The Crypto Landscape Will Change In 2025 And Beyond</a></li>
</ul>
Top Gainers:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Maker DAO (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/mkr/usd">MKR</a>)</td>
<td>&nbsp;$1,562</td>
<td>+17.5%</td>
</tr>
<tr>
<td>Ethena (CRYPTO: ENA)</td>
<td>&nbsp;$0.508</td>
<td>+12.8%</td>
</tr>
<tr>
<td>Cardano (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>)</td>
<td>&nbsp;$0.4017</td>
<td>+11.5%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Trader Smileycapital <a href="https://x.com/smileycapital/status/1854635968659132728">cautioned</a> that &#8220;less is more&#8221; and predicts a &#8220;wealth effect&#8221; from increasing valuations in Bitcoin, Ethereum and Solana to trickle down to small-cap cryptocurrencies.
Analyst Ali Martinez expects the start of an altseason soon:
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Altseason hasn't even begun! We're in that part of the cycle where <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> is still outpacing <a href="https://twitter.com/hashtag/Ethereum?src=hash&amp;ref_src=twsrc%5Etfw">#Ethereum</a>—totally normal at this stage. This could be the ideal time to stack up on altcoins, as history shows that altseason often follows shortly after. <a href="https://t.co/jxANVYk8kt">pic.twitter.com/jxANVYk8kt</a>
&mdash; Ali (@ali_charts) <a href="https://twitter.com/ali_charts/status/1854623178523328901?ref_src=twsrc%5Etfw">November 7, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Veteran analyst Benjamin Cowen pointed out that Bitcoin is following a familiar pattern to previous bull market cycles:
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/BTC?src=hash&amp;ref_src=twsrc%5Etfw">#BTC</a> still just doing what it always does at this point in the market cycle <a href="https://t.co/jK6F631PuG">pic.twitter.com/jK6F631PuG</a>
&mdash; Benjamin Cowen (@intocryptoverse) <a href="https://twitter.com/intocryptoverse/status/1854619730880889182?ref_src=twsrc%5Etfw">November 7, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
What&#8217;s Next: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41783773/the-future-of-crypto-regulation-under-a-trump-administration-headwinds-are-now-tailwinds">The Future Of Crypto Regulation Under A Trump Administration: &#8216;Headwinds Are Now Tailwinds&#8217;</a></li>
</ul>
Image: Shutterstock.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Topics

Markets

Movers

$ADA

$BTC

$DOGE

$ENA

$ETH

$MKR

$SHIB

$SOL

Bitcoin Hits Fresh All-Time High, Ethereum Rallies: 'Altseason Hasn't Even Begun,' Trader Says

Editors Note: This story has been updated to include a response from a Rocket Lab USA spokesperson and to correct the spelling of the company&#8217;s name in the headline. 
The social media account of&nbsp;Peter Beck, CEO of&nbsp;Rocket Lab USA Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>), was hacked, leading to a fraudulent post about a new crypto-based token.
What Happened: On Wednesday, the unauthorized post from Beck&#8217;s X, formerly Twitter account, promoted a new Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)-based token to fund space-related projects, reported Reuters.
<figure class="wp-block-image size-large"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06202850/Screenshot-2024-11-07-at-6.54.15%E2%80%AFAM-935x1024.png" alt="" class="wp-image-634096" /><figcaption class="wp-element-caption">Screenshot from Peter Back&#8217;s compromised X Account</figcaption></figure>
At the time of writing, the above post from Back&#8217;s account was removed.
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/11/41702294/apple-begins-shifting-iphone-17-production-in-india-cooks-china-optimism-and-more-this-week-in-apple?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Apple Begins Shifting iPhone 17 Production In India, Cook&#8217;s China Optimism, And More: This Week In Appleverse</a>
A major player in the small satellite launch market valued at $6.5 billion, Rocket Lab was working with the platform to regain control of the account.&nbsp;
&#8220;Peter&#8217;s account has been compromised,&nbsp;so this is not an&nbsp;official tweet. We are working&nbsp;with X to restore it,&#8221;&nbsp;a company spokesperson confirmed in an email to Reuters.
Rocket Lab responded to Benzinga&#8217;s email updating about the account&#8217;s restoration. The company&#8217;s CEO also took to X, to share this information.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Account restored, thanks <a href="https://twitter.com/elonmusk?ref_src=twsrc%5Etfw">@elonmusk</a> and the X team for such a speedy fix! <a href="https://t.co/aOYIgeZ7Cd">https://t.co/aOYIgeZ7Cd</a>
&mdash; Peter Beck (@Peter_J_Beck) <a href="https://twitter.com/Peter_J_Beck/status/1854342132099961311?ref_src=twsrc%5Etfw">November 7, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: On Tuesday, Rocket Lab announced the successful launch of its <a href="https://www.benzinga.com/news/24/11/41750137/whats-going-on-with-rocket-lab-stock-tuesday">54th Electron mission</a>, deploying a single satellite to Low Earth Orbit for a confidential commercial customer.
Last month, Rocket Lab&#8217;s shares saw a boost following the Joe Biden administration&#8217;s <a href="https://www.benzinga.com/government/24/10/41392734/rocket-lab-stock-climbs-as-biden-administration-plans-to-ease-export-restrictions-on-space-companies">plans to ease export restrictions</a> on U.S. commercial space companies.
Check out more of Benzinga&#8217;s Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41706934/how-to-master-ios-18s-control-center-tips-to-reset-and-customize-your-iphones-quick-access-hub?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">How To Master iOS 18&#8217;s Control Center: Tips To Reset And Customize Your iPhone&#8217;s Quick Access Hub</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Tech

Media

RKLB

Rocket Lab CEO Thanks Elon Musk And X Team For Speedy Restoration Of Hacked Account: 'Such A Speedy Fix!' (Updated)

Sight Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGHT#NASDAQ">SGHT</a>) affirms FY2024 sales outlook from $81.00 million-83.00 million to $81.00 million-83.00 million.

Guidance

SGHT

Sight Sciences Affirms FY2024 Sales Guidance from $81.00M-83.00M to $81.00M-83.00M

ATA Creativity Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AACG#NASDAQ">AACG</a>) reported quarterly losses of $(0.06) per share. This is a 200 percent decrease over losses of $(0.02) per share from the same period last year. The company reported $9.58 million in sales this quarter. This is a 17.62 percent increase over sales of $8.15 million the same period last year.

AACG

ATA Creativity Glb Q3 Adj ADS $(0.06) Down From $(0.02) YoY, Sales $9.58M Up From $8.15M YoY

Doximity Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) shares are surging in Thursday&#8217;s after-hours session after the company reported better-than-expected financial results<a href="https://www.benzinga.com/pressreleases/24/11/b41823433/doximity-announces-fiscal-2025-second-quarter-financial-results"> for the second quarter</a>.
<ul>
<li>Q2 Revenue: $136.83 million, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $127.15 million</li>
</ul>
<ul>
<li>Q2 Adjusted EPS: 30 cents, versus estimates of 25 cents</li>
</ul>
Revenue was up 20% year-over-year. The company generated $68.3 million in operating cash flow and $66.8 million in free cash flow during the quarter. Free cash flow was up 475% year-over-year. 
&#8220;Our clinical workflow tools saw record use in the second quarter with over 600,000 unique active prescribers. We&#8217;re proud to help physicians save time, so they can provide better care for their patients,&#8221; said Jeff Tangney, co-founder and CEO of Doximity.
Guidance: Doximity expects third-quarter revenue to be in the range of $152 million to $153 million. The company anticipates third-quarter Adjusted EBITDA of $83 million to $84 million.
Doximity sees full-year revenue between $535 million and $540 million. The company expects full-year Adjusted EBITDA to be in the range of $274 million to $279 million.
DOCS Price Action: <a href="https://www.benzinga.com/quote/DOCS" target="_blank" rel="noreferrer noopener">Doximity shares</a> were up 37.91% after hours at $59.88 at the time of publication Thursday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41828399/fortinet-q3-earnings-revenue-beat-eps-beat-billings-up-6-shares-slide">Fortinet Q3 Earnings: Revenue Beat, EPS Beat, Billings Up 6%, Shares Slide</a></li>
</ul>
Photo: Courtesy of Doximity.

Health Care

After-Hours Center

DOCS

Doximity Reports Strong Q2 Earnings Results, Shares Soar

AMN Healthcare Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMN#NYSE">AMN</a>) reported quarterly earnings of $0.61 per share which beat the analyst consensus estimate of $0.57 by 7.02 percent. The company reported quarterly sales of $687.509 million which beat the analyst consensus estimate of $671.445 million by 2.39 percent. This is a 19.44 percent decrease over sales of $853.463 million the same period last year.

AMN Healthcare Services Q3 2024 Adj. EPS $0.61 Beats $0.57 Estimate, Sales $687.509M Beat $671.445M Estimate

Trade Desk shares are trading lower despite the company reporting better-than-expected Q3 financial results.

Globalstar (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GSAT#AMEX">GSAT</a>) reported quarterly sales of $72.307 million which beat the analyst consensus estimate of $60.337 million by 19.84 percent. This is a 25.35 percent increase over sales of $57.683 million the same period last year.

GSAT

Globalstar Q3 Sales $72.307M Beat $60.337M Estimate

Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) reported quarterly earnings of $0.04 per share which missed the analyst consensus estimate of $0.34 by 88.24 percent. This is a 77.78 percent decrease over earnings of $0.18 per share from the same period last year. The company reported quarterly sales of $621.40 million which missed the analyst consensus estimate of $627.15 million by 0.92 percent. This is a 21.60 percent increase over sales of $511.01 million the same period last year.

CORRECTION: Evolent Health Q3 Adj $0.04 Misses $0.34 Estimate, Sales $621.40M Miss $627.15M Estimate

Stantec Expects FY24 Net Revenue Growth Outlook From 12% - 15% To 14.5% - 15.0%, Adjusted EPS Growth Forecast From 12% - 16% To 16% -18%

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.22) by 18.18 percent. The company reported quarterly sales of $24.124 million which beat the analyst consensus estimate of $18.281 million by 31.96 percent. This is a 0.08 percent decrease over sales of $24.144 million the same period last year.

NKTR

Nektar Therapeutics Q3 2024 GAAP EPS $(0.18) Beats $(0.22) Estimate, Sales $24.124M Beat $18.281M Estimate

Red Rock Resorts Q3 2024 Adj EPS $0.48 Misses $0.52 Estimate, Sales $468.00 Beats  $461.67M Estimate

VCTR

Victory Capital Holdings shares are trading higher after the company reported better-than-expected Q3 financial results and raised its quarterly dividend.

Volato Group, Inc. ("Volato," or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#NYSE">SOAR</a>) is excited to announce that Vaunt has reached an important milestone, with the first flyExclusive flights now available on the platform. This is the start of a larger effort to expand the flight options available to Vaunt members, with more additions and features planned in the coming months.
flyExclusive brings a range of light, midsize, and super-midsize jets to Vaunt, significantly expanding the choices available to users. This first step lays the groundwork for future growth, as Volato works to steadily increase flight availability and deliver a more robust platform for private travelers.

SOAR

Volato Group Announces Vaunt Reaches First Milestone With flyExclusive Flights Now Available On The Platform

Open Lending (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPRO#NASDAQ">LPRO</a>) reported quarterly earnings of $0.01 per share which missed the analyst consensus estimate of $0.04 by 75 percent. The company reported quarterly sales of $23.476 million which missed the analyst consensus estimate of $29.379 million by 20.09 percent. This is a 9.73 percent decrease over sales of $26.006 million the same period last year.

LPRO

Open Lending Q3 2024 GAAP EPS $0.01 Misses $0.04 Estimate, Sales $23.476M Miss $29.379M Estimate

Despite claiming over 100,000 lives annually, the U.S. overdose crisis received minimal attention during the recent presidential campaign, which concluded with Donald Trump&#8217;s <a href="https://www.benzinga.com/markets/cannabis/24/11/41776510/cannabis-industry-leaders-react-to-trump-victory-expect-changes">victory</a>. This oversight comes as overdose deaths continue to rise among Black and Indigenous Americans, revealing a growing racial disparity in the epidemic.
<h3 class="wp-block-heading">Rising Racial Disparities In Overdose Deaths</h3>
According to a Stateline analysis of federal data <a href="https://kentuckylantern.com/2024/11/04/overdose-deaths-are-rising-among-black-and-indigenous-americans/">covered</a> by Tim Henderson, overdose deaths among white Americans have declined, but deaths among people of color have increased. In 2023, Black and Native Americans experienced overdose death rates of 49.5 and 39.8 per 100,000 people, respectively, surpassing white rates. Health experts attribute this to a lack of targeted resources and funding in nonwhite communities.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
&#8220;It is our contention that Black harm reduction isn't about drug use, it's about the harms of not being a white person in this country,&#8221; said Tracie Gardner, co-director of the National Black Harm Reduction Network. Communities of color often struggle to access harm reduction services, which are predominantly designed and led by white institutions.
<h3 class="wp-block-heading">Minimal Campaign Attention</h3>
Throughout the campaign, Trump and his opponent, Vice President Kamala Harris, <a href="https://www.benzinga.com/markets/cannabis/24/10/41299527/kamala-harris-defends-immigration-policy-at-latino-town-hall-criticizes-trumps-border-stance">focused largely on border security and drug enforcement</a> rather than harm reduction strategies.&nbsp;
As a recent Fitler Mag <a href="https://filtermag.org/overdose-presidential-election/">article</a> notes, Trump&#8217;s official platform emphasized escalating the drug war, proposing measures like deploying the U.S. Navy to impose a &#8220;full Fentanyl Blockade&#8221; and cracking down on cartels. Harris, while mentioning a commitment to ending the opioid epidemic, highlighted her background in prosecutions and supported increased border security measures.
Public health experts criticize this approach for failing to address the root causes of the crisis. Kassandra Frederique, executive director of the Drug Policy Alliance, noted that efforts have &#8220;ultimately fallen short of the scale and magnitude this crisis demands.&#8221;
<h3 class="wp-block-heading">Rising Demand For Narcan</h3>
Amid this policy void, demand for naloxone—commonly known by the brand name Narcan—is increasing sharply. Over 250 companies, universities and organizations have pledged to provide free doses of the overdose-reversing medication, <a href="https://www.npr.org/sections/shots-health-news/2024/10/08/nx-s1-5145832/250-companies-schools-and-organizations-pledge-to-provide-overdose-antidote-naloxone">according</a> to NPR. Major corporations like Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), United Airlines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) and the National Hockey League are participating in this national effort to curb fatalities.
White House officials noted that the wider availability of naloxone has contributed to a recent 10% decline in overall overdose deaths. &#8220;From airlines to classrooms, from offices to sports arenas, we are grateful to have hundreds of voluntary commitments from organizations and businesses across the country,&#8221; stated Dr. Rahul Gupta, the Biden administration&#8217;s drug czar, prior to the election.
However, experts caution that fatalities remain high, especially among marginalized communities.
<h3 class="wp-block-heading">Emergent BioSolutions Sees Stock Surge</h3>
Meanwhile, Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>), the manufacturer of Narcan, has seen its stock perform strongly in 2024. With a diverse portfolio addressing public health threats, the company&#8217;s financial recovery and strategic government contracts position it favorably in the market, <a href="https://www.insidermonkey.com/blog/emergent-biosolutions-inc-ebs-a-standout-among-best-performing-cheap-stocks-in-2024-1371074/">noted</a> Insider Monkey. EBS reported significant revenue growth and reduced debt, contributing to a year-to-date share price gain of over 280%.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/23/03/31549189/fda-approves-over-the-counter-sale-of-opioid-reversal-drug-narcan">FDA Approves Over The Counter Sale Of Opioid Reversal Drug Narcan</a>
Analysts attribute part of Emergent&#8217;s success to the increasing recognition of naloxone&#8217;s importance in combating the overdose crisis. As more organizations stock Narcan, the company&#8217;s role becomes ever more critical.
<h3 class="wp-block-heading">Barriers To Harm Reduction Access Persist</h3>
As the new administration takes office, the neglect of the overdose crisis in election debates raises questions about the future of <a href="http://benzinga.com/topic/harm-reduction">harm reduction</a> policies under the new administration. Advocates urge the government to prioritize effective strategies over punitive measures.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/41780260/canopy-growth-and-other-top-cannabis-companies-to-report-earnings-will-results-get-pot-stocks-on">Canopy Growth And Other Top Cannabis Companies To Report Earnings: Will Results Get Pot Stocks On Track Following Post-Election Dip?</a></li>
</ul>

Cannabis

Government

Politics

AMZN

Overdose Crisis In Shadows Of Elections As Black, Indigenous Americans Deaths Rise

In a report released today, Nicole Germino from Truist Financial reiterated a Buy rating on Y-Mabs Therapeutics (YMAB – Research Report), with a pr...

Truist Financial Sticks to Their Buy Rating for Y-Mabs Therapeutics (YMAB)

Y-Mabs Therapeutics (YMAB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Etzer Darout...

Buy Rating Affirmed for Y-Mabs Therapeutics Amid Solid R&D Prospects and Resilient Financial Performance

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Tilray (TLRY – Research Report) and Y-Mabs Therapeutics (YMAB – R...

Analysts Offer Insights on Healthcare Companies: Tilray (TLRY) and Y-Mabs Therapeutics (YMAB)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Y-Mabs Therapeutics (YMAB – Research Report), Resm...

Analysts Offer Insights on Healthcare Companies: Y-Mabs Therapeutics (YMAB), Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (AU:RMD) and Bayer (GB:0P6S)

In a report released today, Michael Ulz from Morgan Stanley maintained a Sell rating on Y-Mabs Therapeutics (YMAB – Research Report), with a price ...

Morgan Stanley Remains a Sell on Y-Mabs Therapeutics (YMAB)

Y-mAbs Therapeutics: Slow But Steady Prospect In Rare Cancers

Truist Financial Remains a Buy on Y-Mabs Therapeutics (YMAB)

JonesTrading analyst Justin Walsh has reiterated their bullish stance on YMAB stock, giving a Buy rating today. Justin Walsh's rating is based on s...

Optimistic Buy Rating for Y-Mabs Therapeutics Driven by Innovative SADA PRIT Technology and Strategic Advancements

Y-mAbs and Nobelpharma sign license and distribution agreement for DANYELZA in Japan

The latest update is out from Y-Mabs Therapeutics ( ($YMAB) ). Y-mAbs Therapeutics has signed an exclusive agreement with Nobelpharma to develop an...

Y-mAbs Partners with Nobelpharma for Japan Expansion

TLRY

YMAB

Management

Press Releases

Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer

Legal

Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Stock of Y-mAbs Therapeutics, Inc. - YMAB

Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast

Y-mAbs to Participate in Upcoming Investor Conferences in August

Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments

Y-mAbs to Participate in Upcoming Investor Conferences in September

Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research

Comments

Y-mAbs Therapeutics

Y-mAbs Therapeutics (YMAB) Opciones

Y-mAbs Therapeutics (NASDAQ:YMAB) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL